Pharmaceuticals
Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application
Lunit's AACR 2026 presentations showed how AI-driven biomarkers can improve the efficiency of clinical workflows, uncover spatial features of the tumor microenvironment not captured by conventional methods, and enable integrated analysis to better support treatment decision-making. SEOUL, South ...
2026-04-18 03:00
8836
Penetrium Bioscience Unveils Breakthrough Mechanism Solving 137-Year-Old "Seed & Soil" Paradigm, Opening a New Era for Targeted Cancer Therapy
SEOUL, South Korea, April 17, 2026 /PRNewswire/ -- Penetrium Bioscience (KOSDAQ 187660) today announced compelling new scientific evidence demonstrating, for the first time at the cellular level, the underlying mechanism behind the long-standing "Seed & Soil" theory originally proposed by Stephen...
2026-04-17 15:48
4520
Crystal Pharmatech Becomes First Company in Asia-Pacific to Deploy Dedicated MicroED Platform Through Strategic Collaboration with ELDICO Scientific
Advancing industrialized Microcrystal Electron Diffraction (MicroED) capabilities for global drug development SUZHOU, China, April 16, 2026 /PRNewswire/ -- Crystal Pharmatech is a science-driven CRO/CDMO specializing in solid-state research, preformulation studies, and formulation development an...
2026-04-16 20:00
3058
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
* Piramal Pharma Solutions is a global leader in antibody-drug conjugate (ADC) development and manufacturing, leveraging over 20 years of specialized experience to support partners from early-stage to commercialization. * Ajinomoto Bio-Pharma Services is a leading provider of biopharmaceutical...
2026-04-16 20:00
3417
Harbour BioMed Appoints Dr. Adam Zong as President
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, April 16, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced t...
2026-04-16 15:20
4009
Clicklinks | 14-Day Candidate Antibody Discovery - Sanyou AI-STAL 2.0 Defines the Era of Ultimate Speed in Drug Molecule Discovery
SHANGHAI, April 15, 2026 /PRNewswire/ -- 01 Introduction In the race of innovative drug R&D, whether for antibodies, peptides, or novel binding proteins, the efficiency of early-stage molecule discovery is always the key factor determining project success or failure. However, traditional molec...
2026-04-15 22:00
4582
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the appointment of Dr. Sudha Rao as Chief Scientific Officer (CSO). Dr. Rao is the scientific originat...
2026-04-15 20:00
5503
Taiho Ventures, LLC Celebrates 10th Anniversary
TOKYO and MENLO PARK, Calif., April 15, 2026 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. (Taiho Pharmaceutical) and Taiho Ventures, LLC (TVL), a strategic corporate venture capital (CVC) arm of Taiho Pharmaceutical, announced on April 15 that TVL has reached its 10th anniversary since its est...
2026-04-15 14:00
4426
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
* Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clients * Zero non-conformities demonstrates company's robust quality management system SHANGHAI, April 14, 2026 /PRNewswire/ -- WuXi Biologics...
2026-04-15 10:39
2907
Mexican company Farmacias Similares brings Dr. Simi to Tokyo in Japan debut
A pop-up store is being opened by Farmacias Similares in Shibuya, which is in the heart of Tokyo. TOKYO, April 15, 2026 /PRNewswire/ -- Dressed as a samurai and with his trademark energetic attitude, Dr. Simi—the face of Farmacias Similares— greets curious visitors stopping by the company's pop-...
2026-04-15 06:00
3537
Advances in Parkinson's Disease Cell Therapy: XellSmart Launches a Multicenter Phase II Clinical Trial Following Encouraging Phase I Results
SUZHOU, China, April 14, 2026 /PRNewswire/ -- In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell Therapy (XS411) for Primary Parkinson's Disease". ...
2026-04-14 22:00
4550
Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at American Association for Cancer Research Annual Meeting 2026
Data Demonstrate Activity in HER2-Low and ADC-Resistant Tumor Models, Supporting Advancement Toward IND SHANGHAI and SUZHOU, China, April 14, 2026 /PRNewswire/ -- Phrontline Biopharma today announced the presentation of preclinical data for TJ106, a next-generation biparatopic HER2-targeting ant...
2026-04-14 21:08
3893
Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
SYDNEY, April 14, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Com...
2026-04-14 21:02
3921
Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development
TAIPEI and SAN DIEGO, April 14, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced today the signing of a Memorandum of Understanding (MOU) with GEM YIELD BAHAMAS LIMITED, an affiliate of the global investment firm Global Emerging Mark...
2026-04-14 15:11
4333
Caliway's Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204's Demonstrated Efficacy and Safety Gain Further Academic Recognition
* Clinical results from Caliway's CBL-0204 Phase 2b study of its fat reduction drug candidate CBL-514 for localized fat reduction have been accepted by theAesthetic Surgery Journal (ASJ), a leading academic journal in aesthetic medicine and plastic surgery. * Following the publication of CBL-...
2026-04-13 16:34
4665
Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the e...
2026-04-13 14:24
4069
SINGAPORE STRENGTHENS SARCOMA CARE THROUGH COORDINATED, MULTIDISCIPLINARY APPROACH
NCIS leads multi-institutional effort to develop expert multidisciplinary guidance to improve sarcoma diagnosis, referrals and outcomes SINGAPORE, April 11, 2026 /PRNewswire/ -- Singapore is strengthening its approach to sarcoma care, a rare group of bone and soft tissue cancers that disproporti...
2026-04-11 16:20
4395
Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
SHANGHAI, April 9, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies,today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led...
2026-04-10 08:00
4862
DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
SHANGHAI, April 9, 2026 /PRNewswire/ -- DualityBio ("DualityBio" or the "Company", Stock Code: 9606.HK) today announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate ("ADC") trastuzumab pamirtecan ("T-Pam", also known as DB-1303 or BNT323), has been ...
2026-04-09 19:55
5523
Portrai to Present 11 Posters on AI-Driven Spatial Transcriptomics at AACR 2026
The South Korean spatial biology company unveils new AI agents, foundation models, and spatial biomarkers for oncology drug discovery. SEOUL, South Korea, April 8, 2026 /PRNewswire/ -- Portrai, Inc. today announced it will present 11 posters highlighting its artificial intelligence and spatial t...
2026-04-08 17:50
3515
Week's Top Stories
Most Reposted
Agoda Makes it Easier for Travelers to See Relevant Photos in Reviews
[Picked up by 313 media titles]
2026-05-06 12:00
Tonik Becomes the First Standalone Digital Bank in the Philippines to Achieve Profitability
[Picked up by 295 media titles]
2026-05-12 10:15
Visa amps up the music as Official Payment Partner for the Asia leg of The Weeknd's 'After Hours Til Dawn' Stadium Tour
[Picked up by 293 media titles]
2026-05-11 16:20
Avnet and HKSTP Invite Global Startups to New AI Hardware Launchpad
[Picked up by 288 media titles]
2026-05-12 10:00Peach Blossoms Celebrates Three Massive Wins - Black Pearl Restaurant Guide 2026, Asia's 50 Best Restaurants 2026 Extended List and Tatler Best 20 Restaurants in Singapore 2026
[Picked up by 279 media titles]
2026-05-12 14:00
Most Read
Amadeus delivers solid Q1 2026 growth, and maintains commercial momentum
2026-05-08 18:30
7743
LightInTheBox to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
2026-05-06 20:00
7169
Massimo Group Launches Sentinel 770 HVAC as Part of Sentinel Product Line Targeting Approximately US$10 Million in 2026 Revenue
2026-05-06 21:20
7124
NYSE Content Update: HawkEye 360 to Start Trading after its $416 Million IPO
2026-05-07 21:35
6377
Pony.ai Labor Day Holiday Robotaxi Paid Orders Surge More Than Sixfold
2026-05-08 20:00
6186